Tirzepatide in youth: first real-world data

Adults have years of trial results and real-world follow-up on tirzepatide. Patients under 21 have had a single randomised trial and, until now, no published account of what happens when ordinary clinics prescribe it. A study in the Journal of Pediatric Endocrinology and Metabolism, published on 10 August 2026, starts to fill that gap. It is a retrospective review, meaning researchers looked back through medical records rather than running a planned experiment, covering 74 patients aged 21 or younger who started tirzepatide across three academic centers^[1].

Who was treated, and what changed

The cohort was older than the word youth suggests: median age 18.4 years, with 45.9% female. Most patients, 86.5%, had type 2 diabetes, and 78.4% had already used a GLP-1 receptor agonist (the class of injected drugs that mimic a gut hormone to lower blood sugar and appetite) before starting tirzepatide^[1]. This was a heavily pre-treated group, not patients trying an incretin (blood-sugar and appetite hormone) drug for the first time.

At the first follow-up visit, a median of 102 days after starting, body mass index fell from 42.7 to 42.0, weight fell from 126.2 to 123.9 kg, and BMI z-score (a measure of how far a young person's BMI sits above the average for their age and sex) fell from 2.9 to 2.8. All three changes were statistically significant, meaning unlikely to be chance within this dataset^[1]. Among the 58 patients with type 2 diabetes, hemoglobin A1c (a blood marker that reflects average glucose over roughly three months) fell from 8.0% to 7.2%, and among the 24 using basal insulin, the long-acting background form, the daily dose fell from 59.7 to 43.9 units^[1]. All four measures remained significantly below baseline at the second follow-up^[1].

The researchers also asked who responded best. In patients with type 2 diabetes, prior GLP-1 receptor agonist use and partial nonadherence (missing doses) were associated with smaller A1c reductions, while a higher starting A1c and a higher tirzepatide dose were associated with larger ones^[1]. A drug that comes after other incretin therapy has less room to move the same marker, which is exactly what the numbers show.

How this sits next to the paediatric trial

The one randomised trial in this age group is SURPASS-PEDS, published in The Lancet in October 2025. It assigned 99 participants aged 10 to 17 with type 2 diabetes, mean age 14.7, to tirzepatide 5 mg, tirzepatide 10 mg, or placebo. At week 30, A1c fell by an average of 2.23 percentage points in the pooled tirzepatide groups against a 0.05-point rise on placebo, and BMI fell 7.4% and 11.2% in the two dose groups against 0.4% on placebo^[2].

Set the two side by side and the real-world result is directionally the same but smaller: a 0.8-point A1c fall in clinics against 2.23 points in the trial^[1][2]. Part of that gap is the population. Trial participants were younger, and the real-world cohort had mostly already taken a GLP-1 drug, which the study itself links to smaller further gains^[1]. Part of it is design. Trials control dose escalation, follow-up contact and adherence support in ways a busy clinic cannot.

The adult benchmark these patients are compared against

Public expectations for tirzepatide were set by adult trials like SURMOUNT-1, where 2,539 adults with obesity lost an average of 15.0% to 20.9% of body weight over 72 weeks depending on dose, against 3.1% on placebo^[3]. The youth cohort lost about 2.3 kg over roughly 14 weeks. Those figures are not in conflict; they describe different windows. Seventy-two weeks of supervised dose escalation is a different exposure to the first three months of a routine prescription, and our tirzepatide overview separates trial timelines from real-world ones for exactly this reason.

What the label currently allows

In the United States, tirzepatide for type 2 diabetes, sold as Mounjaro, is indicated for adults and for pediatric patients aged 10 years and older^[4]. Tirzepatide for weight management, sold as Zepbound, is indicated for adults only, and its label states that safety and effectiveness have not been established in pediatric patients^[5]. So a young person with type 2 diabetes and obesity fits inside the labelled use, while a young person with obesity alone does not. Because 86.5% of this cohort had type 2 diabetes, most prescriptions sat on label, but the obesity-only share was prescribed off-label, a detail worth knowing when reading outcome averages^[1][4][5].

What a study like this cannot tell you

Retrospective chart reviews answer a narrower question than trials. There was no placebo or comparison group, so the improvements cannot be cleanly separated from everything else happening in these patients' care. Everyone included had at least one follow-up visit, which quietly removes patients who stopped early or never returned, often the ones with the worst results. Three academic centers are not typical clinics. And the regression findings are associations: prior GLP-1 use tracks smaller A1c falls, but that does not prove the earlier drug caused the difference^[1]. Confounding, where treated and untreated groups differ in ways the data cannot fully capture, is the standing limitation of every study built this way.

Where this lands

Read conservatively, this study says tirzepatide in specialist youth clinics behaves the way the trial said it should: blood sugar down, weight and BMI down, insulin needs down, with smaller gains in patients arriving off other incretin drugs^[1][2]. It does not settle long-term safety, durability past a few months, or what happens in general practice. For the broader picture of approved uses, dosing literature and open questions, see our tirzepatide page.

This article is educational and is not medical advice. Decisions about treatment for type 2 diabetes or obesity in anyone under 21 belong with a qualified healthcare provider who knows the patient.